<DOC>
	<DOCNO>NCT01720290</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare repaglinide metformin administer alone combination subject type 2 diabetes .</brief_summary>
	<brief_title>Comparison Repaglinide Metformin Administered Alone Combination Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Previously treat oral hypoglycaemic agent ( OHA ) monotherapy ( metformin , less 1500 mg daily ) Body Mass Index ( BMI ) 2135 kg/m^2 HbA1c ( glycosylated haemoglobin A1c ) 7.010 % Treatment insulin within last 3 month precede trial Uncontrolled treat untreated hypertension ( systolic blood pressure equal 180 mm Hg , and/or diastolic blood pressure 105 mm Hg ) Participation clinical trial within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>